(Q30668895)

26 June 2017

title

MYSTIC program: summary of European data from 1997 to 2000. (English)

1 reference

26 June 2017

H Goossens

1

1 reference

26 June 2017

MYSTIC Study Group (Europe)

series ordinal

2

1 reference

26 June 2017

publication date

1 December 2001

1 reference

Diagnostic Microbiology and Infectious Disease

26 June 2017

published in

1 reference

26 June 2017

volume

41

1 reference

26 June 2017

issue

4

1 reference

26 June 2017

page(s)

183-189

1 reference

Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Meropenem: a microbiological overview

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Bacterial resistance: a worldwide problem

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Diffusion of beta-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

The MYSTIC (meropenem yearly susceptibility test information collection) programme.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

Interactions of meropenem with class I chromosomal beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900320-0

7 January 2021

10.1016/S0732-8893(01)00320-0

Identifiers

DOI

1 reference

26 June 2017

1 reference